UPDATE: Citadel Securities Initiates Coverage on Vertex

Citadel Securities has published a report on Vertex VRTX initiating coverage on the medicine developer. In the report, Citadel Securities wrote, "We are initiating coverage of Vertex Pharmaceuticals (VRTX) with a Neutral rating and $46 price target. While the launch of Incivek for HCV is progressing well, significant revenues currently appear priced into VRTX shares." Citadel Securities rated Vertex a Neutral with a price target of $46.00. Vertex closed Friday at $43.00.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorInitiationAnalyst RatingsBiotechnologycitadel securitiesHealth Carevertex
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!